Integra LifeSciences Holdings Corporation $IART Shares Purchased by Allianz Asset Management GmbH

Allianz Asset Management GmbH boosted its position in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 53.7% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 229,904 shares of the life sciences company’s stock after acquiring an additional 80,290 shares during the quarter. Allianz Asset Management GmbH owned about 0.30% of Integra LifeSciences worth $2,821,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in IART. Wellington Management Group LLP lifted its position in Integra LifeSciences by 10.4% during the 1st quarter. Wellington Management Group LLP now owns 2,766,125 shares of the life sciences company’s stock worth $60,827,000 after acquiring an additional 259,987 shares during the period. Nuveen LLC purchased a new position in shares of Integra LifeSciences during the 1st quarter valued at about $5,118,000. Victory Capital Management Inc. raised its stake in shares of Integra LifeSciences by 1,067.6% during the 1st quarter. Victory Capital Management Inc. now owns 147,982 shares of the life sciences company’s stock valued at $3,254,000 after buying an additional 135,308 shares during the last quarter. Alliancebernstein L.P. raised its stake in shares of Integra LifeSciences by 5.0% during the 1st quarter. Alliancebernstein L.P. now owns 2,706,434 shares of the life sciences company’s stock valued at $59,514,000 after buying an additional 128,041 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Integra LifeSciences by 9.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,146,921 shares of the life sciences company’s stock valued at $25,221,000 after buying an additional 99,348 shares during the last quarter. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Price Performance

NASDAQ:IART opened at $16.12 on Friday. Integra LifeSciences Holdings Corporation has a 12 month low of $11.06 and a 12 month high of $27.13. The stock has a 50 day moving average of $14.72 and a two-hundred day moving average of $13.99. The company has a current ratio of 1.23, a quick ratio of 0.73 and a debt-to-equity ratio of 1.18. The firm has a market cap of $1.26 billion, a P/E ratio of -2.47 and a beta of 1.21.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Thursday, July 31st. The life sciences company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.43 by $0.02. Integra LifeSciences had a positive return on equity of 12.15% and a negative net margin of 30.87%.The company had revenue of $415.61 million during the quarter, compared to analyst estimates of $395.06 million. During the same period in the previous year, the business earned $0.63 EPS. Integra LifeSciences’s quarterly revenue was down .6% on a year-over-year basis. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. On average, analysts expect that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on IART. Truist Financial set a $15.00 price objective on Integra LifeSciences and gave the company a “hold” rating in a research note on Wednesday, October 15th. Citigroup restated a “sell” rating and issued a $12.00 price target (up previously from $10.00) on shares of Integra LifeSciences in a research note on Tuesday, October 7th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Integra LifeSciences in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat, Integra LifeSciences has a consensus rating of “Reduce” and a consensus price target of $16.17.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.